Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 113

1.

GH replacement in 1034 growth hormone deficient hypopituitary adults: demographic and clinical characteristics, dosing and safety.

Abs R, Bengtsson BA, Hernberg-Stâhl E, Monson JP, Tauber JP, Wilton P, Wüster C.

Clin Endocrinol (Oxf). 1999 Jun;50(6):703-13.

PMID:
10468941
2.

Long-term growth hormone replacement therapy in hypopituitary adults.

Verhelst J, Abs R.

Drugs. 2002;62(16):2399-412. Review.

PMID:
12396230
3.
4.

Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.

Plosker GL, Figgitt DP.

Pharmacoeconomics. 2004;22(6):389-411. Review.

PMID:
15099124
5.
6.

How much, and by what mechanisms, does growth hormone replacement improve the quality of life in GH-deficient adults?

Chrisoulidou A, Kousta E, Beshyah SA, Robinson S, Johnston DG.

Baillieres Clin Endocrinol Metab. 1998 Jul;12(2):261-79. Review.

PMID:
10083896
7.

Safety of growth hormone replacement therapy in adults.

Gibney J, Johannsson G.

Expert Opin Drug Saf. 2004 Jul;3(4):305-16. Review.

PMID:
15268648
8.

Long-term experience with GH replacement therapy: efficacy and safety.

Monson JP.

Eur J Endocrinol. 2003 Apr;148 Suppl 2:S9-14. Review.

9.

The consequences of growth hormone deficiency in adulthood, and the effects of growth hormone replacement.

Christ ER, Carroll PV, Russell-Jones DL, Sönksen PH.

Schweiz Med Wochenschr. 1997 Aug 30;127(35):1440-9. Review.

PMID:
9297747
10.

Age-related changes in growth hormone secretion: should the somatopause be treated?

Cummings DE, Merriam GR.

Semin Reprod Endocrinol. 1999;17(4):311-25. Review.

PMID:
10851571
11.

Cardiovascular risk factors in hypopituitary GH-deficient adults.

Verhelst J, Abs R.

Eur J Endocrinol. 2009 Nov;161 Suppl 1:S41-9. doi: 10.1530/EJE-09-0291. Epub 2009 Aug 14. Review.

12.

The use of self-rating questionnaires as a quantitative measure of quality of life in adult growth hormone deficiency.

Murray RD, Shalet SM.

J Endocrinol Invest. 1999;22(5 Suppl):118-26. Review.

PMID:
10442581
13.

Growth hormone replacement therapy for growth hormone-deficient adults.

Powrie J, Weissberger A, Sönksen P.

Drugs. 1995 May;49(5):656-63. Review.

PMID:
7601008
14.

Growth hormone deficiency and cardiovascular risk.

Hew FL, O'Neal D, Kamarudin N, Alford FP, Best JD.

Baillieres Clin Endocrinol Metab. 1998 Jul;12(2):199-216. Review.

PMID:
10083892
15.

How useful are serum IGF-I measurements for managing GH replacement therapy in adults and children?

Pawlikowska-Haddal A, Cohen P, Cook DM.

Pituitary. 2012 Jun;15(2):126-34. doi: 10.1007/s11102-011-0343-y. Review.

PMID:
21909971
16.

Long-term effects of growth hormone therapy on intermediary metabolism and insulin sensitivity in hypopituitary adults.

Johnston DG, Al-Shoumer KA, Chrisoulidou A, Kousta E, Beshyah S, Robinson S.

J Endocrinol Invest. 1999;22(5 Suppl):37-40. Review.

PMID:
10442569
17.

GH-replacement therapy in adults.

Christiansen JS, Jørgensen JO, Pedersen SA, Müller J, Jørgensen J, Møller J, Heickendorf L, Skakkebaek NE.

Horm Res. 1991;36 Suppl 1:66-72. Review.

PMID:
1806489
19.

The influence of growth hormone (GH) deficiency and GH replacement on quality of life in GH-deficient patients.

Deijen JB, van der Veen EA.

J Endocrinol Invest. 1999;22(5 Suppl):127-36. Review.

PMID:
10442582
20.

GH therapy and cancer risk in hypopituitarism: what we know from human studies.

Pekic S, Popovic V.

Eur J Endocrinol. 2013 Oct 1;169(5):R89-97. doi: 10.1530/EJE-13-0389. Print 2013 Nov. Review.

Supplemental Content

Support Center